Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2020

View Archived Issues

GT Biopharma advances new TriKE therapy for breast and gastrointestinal cancers

Intra-Cellular initiates clinical programs for ITI-LLAI and ITI-333

MATR3 S85C knock-in mice mimic behavioral and neuropathological features of human early-stage ALS

RCAN1 is involved in tubulointerstitial fibrosis progression by regulating mitochondrial quality

Novel lipid conjugates of APJ agonist peptides show prolonged half-life for once-daily dosing

YF17D-based COVID-19 vaccine candidate induces protective immunity within 10 days with a single dose

Max-Delbrueck-Centrum fuer Molekulare Medizin, DZNE patent chimeric autoantibody receptors

New mutant LRRK2 inhibitors identified at Merck & Co.

Compounds for treating rabies patented by Oita University Institute of Advanced Medicine

BIAL-Portela & Ca. discovers dopamine beta-monooxygenase inhibitors

3M Pharmaceuticals presents new TLR7/8 agonists

Phase IIb/III trial of Zyesami for respiratory failure in critical COVID-19 completes enrollment

Hepion reports topline low-dose data from phase IIa trial of CRV-431 in NASH

Vaxil offers update on COVID-19 vaccine research

FDA issues complete response letter for Osmotica's arbaclofen ER for MS spasticity

NUSAP1 linked to poor prognosis in chronic lymphocytic leukemia

U.K. MHRA authorizes AstraZeneca's COVID-19 vaccine for emergency supply

New clinical program studies Emergent's COVID-HIG product candidate for COVID-19 prophylaxis

COVID anniversary coincides with more transmissible strains

Final results from phase III BRIDGE study of pegunigalsidase alfa for Fabry disease

Opdivo SCLC indication withdrawn in U.S.

Polish authorities grant new indication for Dexaven to treat COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...